Celerion, a contract research organization (CRO) known to be a leader in early-stage safety-based studies, has roots in the Midwest that go back 80 years. Recently, the company reported its successful reaccreditation by the Association for the Accreditation of Human Research Protection Program (AAHRPP). The CRO touts that it’s the only CRO to receive the AAHRPP accreditation. If this is in fact the case, TrialSite suggests more CROs start considering human safety accreditation.
AAHRPP accreditation indicates that the organization that takes the time and effort to go through the accreditation process follows rigorous standards for ethics, quality and protections for human research. AAHRPP promotes high-quality research through an accreditation process that helps organizations worldwide strengthen their human research protection programs (HRPPs). As the “gold seal,” AAHRPP accreditation offers assurances, for example to research participants and sponsors, that an HRPP is focused first and foremost on excellence.
Now Celerion announces its reaccreditation, and, according to its recent press release, is the only such contract services firm to achieve this accreditation. Philip Bach, Vice President of Global Clinical Research commented, “As the sole contract research organization (CRO) receiving this accreditation from AAHRPP, Celerion continues to position itself at the forefront of superior ethical and safety standards in clinical research.
Organizations applying for accreditation or reaccreditation must demonstrate thorough policies, procedures and practices and their ongoing commitment to ensuring human rights protection in clinical research
Celerion’s roots in Lincoln, Nebraska, go way back to 1933 when the legacy company called Harris Laboratories got its start. Fast forward many decades, and Celerion was formed in 2010 through the acquisition of the early stage development operations of MDS Pharma Services. Prior to that, the facility in Lincoln conducted business under the name MDS Harris, following the acquisition by MDS Inc., an international healthcare organization.
The company has been conducting clinical trials since 1969 and has completed over 6,000 studies to date. With extensive capacity for early stage Phase 1 research, their facilities offer over 600 beds and a pool of talented professionals with deep expertise in clinical trials.
Now a recognized global leader in early clinical research services, Celerion ‘translates science into medicine” through scientific excellence, medical expertise and broad clinical operations experience.